Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma

By C. Lawrie, S. Gal, Heather M. Dunlop, Beena Pushkaran, A. Liggins, K. Pulford, A. Banham, F. Pezzella, J. Boultwood, J. Wainscoat and 2 more. British Journal of Haematology, 2008

1,768 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/42634c3921ea5272c7c14db7d1db7273f9c7f117

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. (2010, background): “Recent studies by both us and others implied that the unique patterns of serum miRNAs may serve as noninvasive biomarkers for cancer development and prognosis.(12-15,28) Therefore, determination of miRNA signatures in patients by using qRT-PCR to assess the profile of a small number of miRNAs as sho”
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “It was found that the cell-free miRNAs in plasma could also be detected and expressed in platelets, erythrocytes, and nucleated blood cells [27,28].”
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. (2009, background): “In malignant states, circulating mRNAs in renal cell carcinoma patients [16] as well as miRNAs from the serum of patients with diffuse large B cell lymphoma [17] have been shown to be stable and highly predictive of malignancy as well as survival.”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “…neoplasias was shown to reﬂect the pattern observed in the tumour tissues, suggesting the attractive possibility of using circulating miRNAs as easily detectable tumour biomarkers (Lawrie et al, 2008), especially for early diagnosis (Heneghan et al, 2010; Huang et al, 2010; Xing et al, 2010).”
Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles (2014, background): “Since circulating miRNAs in serum was first reported [75], a tremendous growth of interest is attracted to the feasibility of circulating miRNAs as potential biomarkers in gastrointestinal malignancies diagnosis.”
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies (2011, background): “org Cancer Prev Res; 5(3) March 2012 495”
Circulating microRNAs in plasma of patients with gastric cancers (2010, background): “In fact, accumulating reports also suggest the potential of miRNAs in the early detection of patients with several malignancies, such as lymphoma, colorectal cancer, tongue cancer and ovarian cancer (Lawrie et al, 2008; Wong et al, 2008; Ng et al, 2009; Resnick et al, 2009).”
Circulating miRNAs are correlated with tumor progression in prostate cancer (2011, background): “were the first to show the presence of miRNAs in body fluids of patients suffering from B-cell lymphoma.(6) Using a mouse model, Mitchell et al.”
Cell-free nucleic acids as biomarkers in cancer patients (2011, background): “In 2008, the presence of miRNAs in serum was first described for patients with diffuse large B cell lymphom”